Article citationsMore>>

Calland, N., Sahuc, M.-E., Belouzard, S., Pène, V., Bonnafous, P., Mesalam, A.A., Deloison, G., Descamps, V., Sahpaz, S., Wychowki, C., Lambert, O., Brodin, P., Duverlie, G., Meuleman, P., Rosenberg, A.R., Dubuisson, J., Rouillé, Y. and Séron, K. (2015) Polyphenols Inhibit Hepatis C Virus Entry by a New Mechanism of Action. Journal of Virology, 89, 10053-10063.
https://doi.org/10.1128/JVI.01473-15

has been cited by the following article:

• TITLE: Inhibition of Herpes Simplex Virus-1 by the Modified Green Tea Polyphenol EGCG-Stearate

  AUTHORS: Shivani N. Patel, Sandra D. Adams, Lee H. Lee

  KEYWORDS: HSV-1, EGCG-Stearate, EGCG, Antiviral, A549 Cells

  JOURNAL NAME: Advances in Bioscience and Biotechnology, Vol.9 No.12, December 28, 2018

  ABSTRACT: Epigallocatechin gallate (EGCG), a green tea polyphenol possesses antioxidant, antibacterial, anticancer and antiviral properties. EGCG-Stearate (EGCG-S) is of interest for this study because of its stability and lipophilic properties. The chemical modification of EGCG-S increased its lipid solubility. Herpes simplex virus-1 (HSV-1), a member of the family Herpesviridae, and Alphaherpesvirinae subfamily is a leading cause of human viral diseases in the United States. In this study, 25 μM, 50 μM, 75 μM, and 100 μM of EGCG and EGCG-S were used to carry out cytotoxicity, cell viability and cell proliferation assays to determine the maximum non-cytotoxic concentrations on cultured A549 cells. The results suggested that 75 μM of EGCG and EGCG-S is the appropriate concentration to further study the effect on the infection of HSV-1 in A549 cells. Infectivity, antiviral, and inverted microscopy assays were performed to study the effects of EGCG and EGCG-S on HSV-1 infection. An antiviral assay was performed using luminescence and it indicated that EGCG-S treated HSV-1 showed up to 90% inhibition. Confocal microscopy images further supported the inhibitory effects of 75 μM EGCG-S on HSV-1 infection in A549 cells. The long-term goal of this research is to use EGCG-S as a possible novel topical therapeutic treatment to limit the spread of HSV-1 infections.